Mohammad AskarPublic working copy · medical review pending

Retinal and choroidal disease · 122

Retinal and choroidal disease: Coats, sickle cell, CSC, high myopia and vascular syndromes

Name the leading sign, exclude the dangerous differential and state what imaging and evidence can actually support.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Coats disease is sporadic, not inherited, and every leukocoria needs retinoblastoma excluded. Proliferative sickle retinopathy is a particular risk in HbSC. Acute CSC is often observed for three to four months, and selected eyes can be treated earlier. High myopia is refractive; pathologic myopia is structural.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Reading a retinal or choroidal case

Retinal and choroidal diseases can cause leaking vessels, ischaemia, subretinal fluid, abnormal tissue or haemorrhage. Describe the pattern first, then check dangerous alternatives and the clinical context. Read every retinal or choroidal case in a fixed order: which structure is affected, which sign leads, which dangerous differential must be excluded, which imaging answers the question, and what the evidence can support. 1

Describe the finding before naming the disease, and distinguish a study result from its applicability to this eye. The original covers Coats disease, sickle-cell retinopathy, CSC, myopia and the vascular syndromes Purtscher, VHL and Wyburn-Mason; all are retained here. 1

02Leukocoria and Coats disease

Leukocoria, the white pupillary reflex, is the commonest presenting sign of retinoblastoma, the most common intraocular malignancy of childhood. Any leukocoria therefore needs fundus examination and specialist referral to exclude retinoblastoma before another diagnosis is accepted. Coats disease is an idiopathic retinal vascular disorder with telangiectasia and intraretinal or subretinal exudation without appreciable retinal or vitreous traction. It is sporadic, not inherited, and not associated with systemic abnormalities. 1 2 4

The original “6 to 8 years” and “99% unilateral, mostly boys” are historical teaching figures. The source review describes the typical presentation as unilateral involvement in young males, with most cases diagnosed in the first or second decade. Age and laterality support the diagnosis but do not exclude it. Keep Coats-like exudative retinopathy separate from Coats disease. Coats-like changes occur in retinitis pigmentosa, where CRB1 mutations are a reported risk factor, and CRB1-negative cases exist. A Coats-like picture therefore raises the question of an inherited retinal dystrophy. 1 2 3

Signs are massive yellow subretinal lipid exudation and peripheral vascular aneurysms with extreme permeability. Wide-field angiography shows the peripheral telangiectasia, and OCT quantifies macular exudation and fluid. Treatment aims to destroy leaking sources with laser photocoagulation or cryotherapy; anti-VEGF can be used as an adjuvant. Stage and exudation guide the choice, and younger patients with more advanced disease have a worse visual prognosis. 1 2

The original “observation in amblyopia” must not become a rule. Amblyopia alone is not a reason to watch a child with active exudation: pain, a structurally threatened eye, the disease stage and macular involvement decide whether treatment is needed. Observation is a judgement in a chronically damaged eye with little visual potential. Red flag: every suspected leukocoria needs retinoblastoma excluded first. The peripheral location of Coats aneurysms supports Coats disease but does not replace that exclusion. 1 2 4

Sporadic Coats disease does not itself establish a hereditary family-screening indication. Suspected retinoblastoma or a Coats-like inherited retinal dystrophy requires its own genetic and family assessment; do not apply the same rule to all leukocoria. 2 3 4

03Sickle-cell retinopathy

Sickle retinopathy results from aggregation of abnormal haemoglobin in the retinal microcirculation, with reduced red-cell deformability, stagnant flow, thrombosis and ischaemia. The eye is an indicator of systemic disease. Proliferative retinopathy and its complications are more common and more severe in HbSC than in HbSS. The original statement about “oval complications” should be read as proliferative retinopathy risk, not as every ocular complication. 1 5 6

Crises are precipitated by hypoxia, acidosis and hyperosmolarity. The original dehydration example after alcohol is plausible but is not a treatment recipe: avoid dehydration and hypoxia and treat a systemic crisis with the haematology team. “Massive intravenous hydration” is not a stand-alone ophthalmological instruction. Fluid management in a sickle-cell crisis is individual and over-hydration has its own risks; the ophthalmic task is to recognise ischaemia and arrange coordinated systemic and retinal care. 1 5

Recognise salmon-patch retinal haemorrhage, black-sunburst pigment change after haemorrhage and sea-fan neovascularisation at the ischaemic periphery. The original pre-/subretinal localisation and RPE/haemosiderin explanation need the matching anatomical source; the names alone do not define the retinal layer. Fluorescein angiography shows peripheral non-perfusion and sea-fan leakage; wide-field imaging and OCT angiography add structural detail. Peripheral laser is considered for proliferative disease to prevent visual loss, although the evidence is not strong. 1 5

Scleral buckling has been associated with anterior-segment ischaemia in sickle-cell disease because it can compromise an already critical perfusion. That is a risk to plan around, not an absolute prohibition of every modern procedure: a 2024 series reported combined buckling and vitrectomy without anterior-segment ischaemia and without routine preoperative transfusion. Practical rule: coordinate surgery with haematology, avoid dehydration and hypoxia, avoid unnecessary intraocular pressure elevation, and document the individual plan. 5 6

The 2024 retrospective referral series included 65 eyes of 61 patients; among 52 detachment eyes, single-operation anatomical success was 72.4% with buckle plus vitrectomy versus 47.8% with vitrectomy alone (P=0.07). Selection, small groups and absence of reported anterior-segment ischaemia do not prove equivalence or eliminate a rare risk; transfusion decisions remain individual. 6

04Central serous chorioretinopathy

CSC belongs to the pachychoroid spectrum: subretinal fluid appears after choroidal abnormality and dysfunction of the outer blood-retina barrier. Acute CSC can often be observed for up to three to four months after diagnosis, and early treatment with half-dose or half-fluence PDT may benefit selected cases. The original claim that intervention is mandatory after four to eight weeks and that the old three-month wait is obsolete overstates the evidence. 1 7

Steroids are the classic modifiable trigger. Ask specifically about nasal sprays, skin creams, joint or soft-tissue injections and oral steroids, not only about eye drops. Stress and a “type-A personality” are traditional associations, not a proven cause. Do not tell a patient that personality caused the disease; discuss stress as a possible modifier while the biology remains choroidal. 1 7

Imaging: “smoke-stack” leakage is classic on angiography but not universal; OCT shows subretinal fluid and choroidal thickening, and autofluorescence informs RPE integrity and chronicity. Half-dose PDT reduces the verteporfin dose; half-fluence PDT reduces the light dose. They are different modifications and not interchangeable terms. A retrospective comparison found faster fluid resolution with half-dose at one month with similar safety; the guideline accepts either for selected acute and for chronic CSC. 1 7 8

Eplerenone is not first-line treatment for chronic CSC. In the VICI randomised trial (57 versus 57 participants with treatment-naive chronic CSC of at least four months), the 12-month visual acuity difference was 1.73 letters (95% CI −1.12 to 4.57; p=0.24), with hyperkalaemia in eight participants per group. In chronic CSC with focal non-central leakage, conventional focal laser is an option if PDT is unavailable. CSC with macular neovascularisation is treated with PDT and/or anti-VEGF. 7 8

The 56-patient half-dose/half-fluence comparison was retrospective; absence of observed RPE atrophy does not establish equal long-term safety. In VICI, the confidence interval crossed no difference; the trial did not show superior 12-month acuity with eplerenone, and co-treatment and discontinuation complicate interpretation. 8 9

05High myopia and myopic maculopathy

High myopia is a refractive definition: spherical equivalent −6.00 D or less in the IMI classification. Pathologic myopia is a structural diagnosis: myopic maculopathy such as posterior staphyloma, atrophy, lacquer cracks or choroidal neovascularisation, with or without high refraction. The original “greater than 26.5 mm axial length” is a commonly quoted orientation value, not a diagnostic threshold for pathologic myopia. Axial length supports the assessment; structural change defines the disease. 1 9

The peripheral retina is thin in high myopia while the macula may appear relatively normal in thickness. That does not guarantee preserved central vision: myopic maculopathy can damage the fovea through atrophy, traction or neovascularisation. Lattice degeneration in an asymptomatic myopic eye is usually not lasered prophylactically. The original exception (symptoms or family history of detachment) bundles different risks; family history alone is not a laser indication. Treat individual high-risk lesions and explain flashes, floaters or a field defect as urgent symptoms. 1 9

A subretinal haemorrhage in a myopic eye is not automatically a CNV. Distinguish a haemorrhage from a lacquer crack, which may resolve without intervention, from myopic CNV, which needs anti-VEGF. Myopic CNV is a diagnosis, not an injection reflex: use OCT and, where needed, fluorescein or OCT angiography to show the neovascular membrane and its activity. A “safety injection” without a diagnosis exposes the eye to injection risk without a target. 1 10

Anti-VEGF is the most effective treatment for myopic CNV: a network meta-analysis of 34 studies (2098 eyes) found a gain of 14.1 letters (95% CI 10.8–17.4) versus untreated eyes in the early phase. In the network meta-analysis, no statistically clear visual difference was found between 1+PRN and 3+PRN, with 1.8 versus 3.2 injections in 12 months. This is not proof of equivalence: heterogeneous studies, indirect comparisons and differing follow-up limit inference. Use activity-based review rather than assuming fewer injections than AMD. 1 10

06Purtscher, VHL and Wyburn-Mason

These diseases make the ophthalmologist a diagnostic gatekeeper for systemic disease, but each has its own level of certainty and its own assessment pathway. Purtscher and Purtscher-like retinopathy show cotton-wool spots and Purtscher flecken (polygonal lesions between vessels) after trauma, acute pancreatitis, SLE and other systemic triggers. Cotton-wool spots are not specific or pathognomonic; they occur in many ischaemic retinopathies. Proposed mechanisms include complement activation and leucoembolisation. 1 11

A systematic review of 168 cases found cotton-wool spots in 58% and Purtscher flecken in 53%; trauma was the leading cause (39.9%), followed by SLE (13.1%) and acute pancreatitis (11.9%). The authors describe the data as low quality; treatment remains treatment of the underlying condition. VHL disease is a hereditary tumour-predisposition syndrome with retinal and CNS haemangioblastomas, renal cell carcinoma, phaeochromocytoma and pancreatic neuroendocrine tumours. A retinal haemangioblastoma therefore requires genetic and systemic assessment, not ophthalmological follow-up alone. 1 11 12

VHL can be diagnosed clinically, but most cases are supported by a pathogenic VHL variant; surveillance starts in childhood and covers retina, CNS, inner ear, kidneys, neuroendocrine glands and pancreas within a multidisciplinary team. Wyburn-Mason (Bonnet-Dechaume-Blanc) syndrome is a congenital, non-hereditary neurocutaneous syndrome with multiple arteriovenous malformations, typically a retinal racemose angioma with a midbrain AVM. Brain imaging is arranged to look for a treatable or life-threatening lesion. 1 12 13

A brain AVM is possible, not inevitable, in every patient with a retinal racemose angioma: the decision for neurological imaging is individual, based on the vascular malformation and symptoms, and is made with neurology and neuroradiology. 13

07Quick review: five rows, with their limits

The table keeps the five original rows and five columns, corrects the two headings that overstated certainty, and adds the qualification that makes each row usable. Read each red flag as a prompt, not a complete rule: leukocoria needs retinoblastoma excluded; HbSC carries the higher proliferative risk; acute CSC is often observed for three to four months; myopic CNV needs a diagnosis before treatment; and Purtscher flecken support but do not prove the syndrome. 1 2 5 7 9 10 11

Quick review: five rows, with their limits
DiseaseLeading finding; check limitsKey diagnostic testTreatment principleExam red flag and limit
Coats diseasePeripheral telangiectasia with lipid exudationWide-field angiography; OCT for the maculaLaser or cryotherapy; anti-VEGF adjuvant; observation only in selected late/damaged eyesSporadic, not inherited; exclude retinoblastoma in every leukocoria. The historical 6–8 years and 99% unilateral are not universal.
Sickle-cell retinopathySea-fan neovascularisation at the ischaemic peripheryFluorescein angiography, plus wide-field or OCT-APeripheral laser for proliferative disease; systemic crisis care with haematologyHbSC carries the higher proliferative risk; avoid dehydration and hypoxia; buckling is an ischaemia risk, not an absolute ban.
CSC / CSRSubretinal fluid with pachychoroid; smoke-stack is not universalOCT; angiography or autofluorescence as neededObserve acute 3–4 months; half-dose or half-fluence PDT for selected acute and chronic casesOriginal “intervene at 1 month” is not mandatory; ask about steroids (nasal spray); stress is an association. Eplerenone is not first-line.
High myopia / myopic maculopathyLacquer cracks, staphyloma, atrophy; CNV is separateOCT with FA or OCT-A as needed; axial length supportsAnti-VEGF for myopic CNV; no prophylactic laser for asymptomatic lattice−6 D or less is refractive; structural change defines pathologic myopia; 26.5 mm alone is not the diagnosis. Confirm CNV before injecting.
Purtscher retinopathyCotton-wool spots and Purtscher flecken, often peripapillaryClinical examination; systemic work-upTreat the underlying conditionCotton-wool spots are not pathognomonic (58% versus flecken 53%); trauma, pancreatitis and SLE are triggers.
What are the main learning points?

Coats disease is sporadic, not inherited, and every leukocoria needs retinoblastoma excluded. Proliferative sickle retinopathy is a particular risk in HbSC. Acute CSC is often observed for three to four months, and selected eyes can be treated earlier. High myopia is refractive; pathologic myopia is structural.

When is assessment urgent?

Leukocoria, sudden visual loss, a new field defect, severe pain or a rapidly progressing detachment needs prompt specialist assessment. In sickle-cell disease, sudden visual loss or a painful red eye with high pressure needs urgent review. Marked inflammation, suspected infection or neurological warning signs also require urgent assessment; the retinal diagnosis must not obscure another acute cause.

References and access status

  1. 1
    Immutable original export; retinal and choroidal teaching export

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Sen, Shields, Honavar, Shields. Coats disease: an overview of classification, management and outcomes. Indian J Ophthalmol 2019;67:763-771. PMID 31124484

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  3. 3
    Sarao, Veritti, Prosperi, Pignatto, Lanzetta. A case of CRB1-negative Coats-like retinitis pigmentosa. J AAPOS 2013;17:414-416. PMID 23871396

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  4. 4
    Rao, Honavar. Retinoblastoma. Indian J Pediatr 2017;84:937-944. PMID 28620731

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  5. 5
    Abdalla Elsayed, Mura, Al Dhibi, et al. Sickle cell retinopathy: a focused review. Graefes Arch Clin Exp Ophthalmol 2019;257:1353-1364. PMID 30895451

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  6. 6
    Rohowetz, Panneerselvam, Williams, et al. Proliferative sickle cell retinopathy: outcomes of vitreoretinal surgery. Ophthalmol Retina 2024;8:832-837. PMID 38302055

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  7. 7
    Feenstra, van Dijk, Cheung, et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res 2024;101:101236. PMID 38301969

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  8. 8
    Lotery, Sivrasad, O’Connell, et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI randomised trial. NIHR Journals Library 2021. PMID 33471454

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  9. 9
    Nicoló, Eandi, Alovisi, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2014;157:1033-1037. PMID 24487046

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  10. 10
    International Myopia Institute. Defining and classifying myopia: a proposed set of standards. PMID 30817826

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  11. 11
    Glachs, Embacher, Berghold, et al. Treatment of myopic choroidal neovascularization: a network meta-analysis and review. Graefes Arch Clin Exp Ophthalmol 2024;262:1693-1722. PMID 37950753

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  12. 12
    Serhan, Abuawwad, Taha, et al. Purtscher’s and Purtscher-like retinopathy: a summative systematic review of 168 cases. PLoS One 2024;19:e0306473. PMID 39240905

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  13. 13
    Binderup, Smerdel, Borgwadt, et al. von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet 2022;65:104538. PMID 35709961

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

  14. 14
    So, Mishra, Holman. Wyburn-Mason syndrome. StatPearls 2023. PMID 29630270

    Complete NCBI abstract independently read by parent15November2026; full article/chapter, figures, tables, protocol and supplements not read or fully appraised. Source-specific design and limits are in the evidence ledger.

Original lecture link